BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, Amos CI, Spitz MR, Wei Q. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 2011;29:4121-8. [PMID: 21947825 DOI: 10.1200/JCO.2010.34.3616] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Cao Z, Song J, Wang J, Guo X, Yu S, Dong W. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. PLoS One 2014;9:e85357. [PMID: 24465544 DOI: 10.1371/journal.pone.0085357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
2 Jiang XE, Xu T, Wei Q, Li P, Gomez DR, Court LE, Liao Z. DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non-small-cell lung cancer. Chronic Dis Transl Med 2018;4:109-16. [PMID: 29988954 DOI: 10.1016/j.cdtm.2018.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Bonanno L. Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2013;2:160-71. [PMID: 25806229 DOI: 10.3978/j.issn.2218-6751.2013.03.07] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
4 Song X, Sturgis EM, Jin L, Wang Z, Wei Q, Li G. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx. Int J Cancer 2013;133:695-704. [PMID: 23335232 DOI: 10.1002/ijc.28051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
5 Zhou Q, Zou BW, Xu Y, Xue JX, Meng MB, Liu FJ, Deng L, Ma DY, Ao R, Lu Y. DNA repair gene polymorphisms and clinical outcome of patients with primary small cell carcinoma of the esophagus. Tumour Biol 2015;36:1539-48. [PMID: 25374063 DOI: 10.1007/s13277-014-2718-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
6 Li L, Zhu T, Gao YF, Zheng W, Wang CJ, Xiao L, Huang MS, Yin JY, Zhou HH, Liu ZQ. Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer. Int J Mol Sci 2016;17:E839. [PMID: 27258253 DOI: 10.3390/ijms17060839] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
7 Cimino GD, Pan CX, Henderson PT. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis 2013;5:369-91. [PMID: 23394702 DOI: 10.4155/bio.12.325] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
8 Yuan Z, Li J, Hu R, Jiao Y, Han Y, Weng Q. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. Sci Rep 2015;5:16482. [PMID: 26585370 DOI: 10.1038/srep16482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
9 Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfikakis PP, Dimopoulos MA, Souliotis VL. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer. PLoS One 2015;10:e0117654. [PMID: 25659114 DOI: 10.1371/journal.pone.0117654] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
10 Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, Zhang W, Zhou HH, Liu ZQ. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer 2019;10:6374-83. [PMID: 31772670 DOI: 10.7150/jca.30139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013;8:e71994. [PMID: 24023723 DOI: 10.1371/journal.pone.0071994] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
12 Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol 2020;11:629266. [PMID: 33628188 DOI: 10.3389/fphar.2020.629266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
13 Stornetta A, Zimmermann M, Cimino GD, Henderson PT, Sturla SJ. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chem Res Toxicol 2017;30:388-409. [PMID: 27936622 DOI: 10.1021/acs.chemrestox.6b00380] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
14 Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One 2013;8:e71140. [PMID: 23990933 DOI: 10.1371/journal.pone.0071140] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
15 Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Adv Ther 2019;36:2638-78. [PMID: 31410780 DOI: 10.1007/s12325-019-01051-z] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 30.0] [Reference Citation Analysis]
16 Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-saccà M, Bon G. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Front Oncol 2022;12:877380. [DOI: 10.3389/fonc.2022.877380] [Reference Citation Analysis]
17 Nasrallah NA, Zhou H, Smith PA, Sears CR. DNA Repair Capacity for Personalizing Risk and Treatment Response - Assay Development and Optimization in Human Peripheral Blood Mononuclear Cells (PBMCs). DNA Repair 2022. [DOI: 10.1016/j.dnarep.2022.103274] [Reference Citation Analysis]
18 Wang Y, He J, Zhang S, Yang Q, Wang B, Liu Z, Wu X. Knockdown of Immature Colon Carcinoma Transcript 1 Inhibits Proliferation and Promotes Apoptosis of Non-Small Cell Lung Cancer Cells. Technol Cancer Res Treat 2017;16:559-69. [PMID: 27413166 DOI: 10.1177/1533034616657977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Shao W, Chen H, He J. The role of SOX-2 on the survival of patients with non-small cell lung cancer. J Thorac Dis 2015;7:1113-8. [PMID: 26380725 DOI: 10.3978/j.issn.2072-1439.2015.07.14] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
20 Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther 2017;16:376-87. [PMID: 27903751 DOI: 10.1158/1535-7163.MCT-16-0381] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
21 Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012;9:144-55. [PMID: 22330686 DOI: 10.1038/nrclinonc.2012.3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
22 Nel I, Gauler TC, Eberhardt WE, Nickel AC, Schuler M, Thomale J, Hoffmann AC. Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. Br J Cancer 2013;109:1223-9. [PMID: 23942068 DOI: 10.1038/bjc.2013.419] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
23 Palomba G, Atzori F, Budroni M, Ombra M, Cossu A, Sini M, Pusceddu V, Massidda B, Frau B, Notari F, Ionta M, Palmieri G. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med 2014;12:272. [PMID: 25253066 DOI: 10.1186/s12967-014-0272-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Park JY, Jang SH. Epidemiology of Lung Cancer in Korea: Recent Trends. Tuberc Respir Dis (Seoul). 2016;79:58-69. [PMID: 27064578 DOI: 10.4046/trd.2016.79.2.58] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 12.8] [Reference Citation Analysis]